Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Inclusion Criteria:

• Participant must have histologic diagnosis of prostate adenocarcinoma

• Participant must have high or very high-risk disease defined by at least one of thefollowing:

• cT3a - cT4x

• Grade group 4 or 5 (Gleason sum 8-10)

• PSA > 20 ng/mL prior to registration

• Participant must have documented evidence of germline mutation (pathogenic/likelypathogenic variant) in BRCA2 or BRCA1 through testing in a Clinical LaboratoryImprovement Act (CLIA)-certified lab

• NOTE: Local lab report is sufficient for eligibility

• Participant may have initiated gonadotrophin releasing hormone (gnRH) agonist, gnRHantagonist, oral anti-androgen (e.g. bicalutamide, nilutamide, flutamide), or otheragent intended to treat prostate cancer prior to registration. The effectiveness ofthe current depot of such treatment must not extend beyond 1 month after studyregistration. Agents listed above cannot be started after participant registration

• Participant must be >= 18 years old

• Participant must have Zubrod performance status of 0-2

• Participant must have a complete medical history and physical exam within 28 daysprior to registration

• Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration)

• Platelets >= 100 x 10^3/uL (within 28 days prior to registration)

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutionalupper limit of normal (ULN) (within 28 days prior to registration)

• Participant must have a serum creatinine =< the institutional upper limit of normal (IULN) OR measured OR calculated creatinine clearance >= 50 mL/min using thefollowing Cockcroft-Gault Formula. This specimen must have been drawn and processedwithin 28 days prior to registration

• Participant must have adequate cardiac function. Participants with known history orcurrent symptoms of cardiac disease, or history of treatment with cardiotoxicagents, must have a clinical risk assessment of cardiac function using the New YorkHeart Association Functional Classification within 28 days prior to registration. Tobe eligible for this trial, participants must be class 2B or better

• Participant with known human immunodeficiency virus (HIV)-infection must bereceiving anti-retroviral therapy and have an undetectable viral load test within 6months prior to registration

• Participant with history of chronic hepatitis B virus (HBV) infection must haveundetectable HBV viral load on suppressive therapy within in 28 days prior toregistration

• Participant with a history of hepatitis C virus (HCV) infection must have beentreated and cured. For participants with HCV infection who are currently ontreatment must have an undetectable HCV viral load within in 28 days prior toregistration

• Participants who are of reproductive potential must have agreed to use an effectivecontraceptive method with details provided as a part of the consent process. Aperson who has semen likely to contain sperm is considered to be of "reproductivepotential." In addition to routine contraceptive methods, "effective contraception"also includes refraining from sexual activity that might result in pregnancy andsurgery intended to prevent pregnancy (or with a side-effect of pregnancyprevention) including vasectomy with testing showing no sperm in the semen

• Prior to registration, participant must have had a urologic consult and be deemed asurgical candidate with known sites of disease deemed by the urologist to bepotentially resectable

• Participants must be offered the opportunity to participate in specimen banking.With participant consent, specimens must be collected and submitted via theSouthwest Oncology Group (SWOG) Specimen Tracking System

• NOTE: As a part of the OPEN registration process the treating institution's identityis provided in order to ensure that the current (within 365 days) date ofinstitutional review board approval for this study has been entered in the system

• Participants must be informed of the investigational nature of this study andmust sign and give informed consent in accordance with institutional andfederal guidelines

• For participants with impaired decision-making capabilities, legally authorizedrepresentatives may sign and give informed consent on behalf of studyparticipants in accordance with applicable federal, local, and CentralInstitutional Review Board (CIRB) regulations

• As part of the registration process the treating institution's identity isprovided in order to ensure that the current (within 365 days) date ofinstitutional review board approval for this study has been entered in thesystem

Exclusion Criteria:

• Participant must not have evidence of distant metastatic disease by conventionalimaging within 90 days prior to registration

• NOTE: cN1 detected only by PSMA-PET is permitted if urologist deems sites ofdisease to be potentially completely resectable

• Participant must not have received prior radiation therapy (RT) to the pelvic region

• Participant must not have a prior or concurrent malignancy whose natural history ortreatment (in the opinion of the treating physician) has the potential to interferewith the safety or efficacy assessment of protocol treatment